By Kimberly Chin 



  GlaxoSmithKline PLC has received the U.S. Food and Drug Administration's approval for the drug Nucala, which treats adult and pediatric patients with hypereosinophilic syndrome, a type of blood disorder. 


  Nucala will become the first and only targeted biologic treatment to win approval for patients with eosinophil-driven disease in the U.S., the company said. Eosinophils are a type of white blood cell. 


  The FDA's approval follows a review of data from the company's Phase 3 study, GlaxoSmithKline said. The results showed 50% fewer patients experienced worsening symptoms or required an escalation in treatment compared with the use of a placebo, the company said. 


  The results were recently published in the Journal of Allergy and Clinical Immunology. 


  Nucala is currently used as treatment for several other eosinophil-driven diseases. 


  Write to Kimberly Chin at kimberly.chin@wsj.com